Certara, Inc. (NASDAQ:CERT) SVP Richard M. Traynor Sells 3,000 Shares

Certara, Inc. (NASDAQ:CERTGet Free Report) SVP Richard M. Traynor sold 3,000 shares of the stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $18.00, for a total transaction of $54,000.00. Following the transaction, the senior vice president now directly owns 173,524 shares of the company’s stock, valued at $3,123,432. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Certara Stock Performance

Shares of CERT stock opened at $16.88 on Thursday. The stock has a market capitalization of $2.70 billion, a P/E ratio of -48.23, a PEG ratio of 1.84 and a beta of 1.63. The company has a current ratio of 2.62, a quick ratio of 2.62 and a debt-to-equity ratio of 0.28. The firm’s 50 day moving average is $17.57 and its 200 day moving average is $15.89. Certara, Inc. has a 12 month low of $11.81 and a 12 month high of $24.96.

Certara (NASDAQ:CERTGet Free Report) last announced its quarterly earnings results on Thursday, February 29th. The company reported $0.05 EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.04). Certara had a negative net margin of 15.62% and a positive return on equity of 4.33%. The business had revenue of $88.01 million for the quarter, compared to analysts’ expectations of $86.80 million. On average, sell-side analysts anticipate that Certara, Inc. will post 0.29 earnings per share for the current year.

Institutional Trading of Certara

Institutional investors and hedge funds have recently bought and sold shares of the company. Tower Research Capital LLC TRC lifted its stake in Certara by 584.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 1,356 shares of the company’s stock worth $25,000 after purchasing an additional 1,158 shares in the last quarter. Pineridge Advisors LLC purchased a new stake in Certara in the 4th quarter worth approximately $28,000. State of Wyoming lifted its stake in Certara by 103.1% in the 2nd quarter. State of Wyoming now owns 2,027 shares of the company’s stock worth $37,000 after purchasing an additional 1,029 shares in the last quarter. Covestor Ltd lifted its stake in Certara by 14,940.0% in the 3rd quarter. Covestor Ltd now owns 3,760 shares of the company’s stock worth $55,000 after purchasing an additional 3,735 shares in the last quarter. Finally, Advisors Asset Management Inc. lifted its stake in Certara by 42.9% in the 3rd quarter. Advisors Asset Management Inc. now owns 4,710 shares of the company’s stock worth $68,000 after purchasing an additional 1,414 shares in the last quarter. 73.96% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on CERT shares. Jefferies Financial Group increased their target price on shares of Certara from $14.00 to $15.50 and gave the company a “hold” rating in a research report on Friday, March 1st. UBS Group increased their target price on shares of Certara from $17.00 to $20.00 and gave the company a “neutral” rating in a research report on Friday, March 1st. Barclays increased their target price on shares of Certara from $16.00 to $18.00 and gave the company an “equal weight” rating in a research report on Thursday, January 25th. SVB Leerink started coverage on shares of Certara in a research report on Monday, February 26th. They set a “market perform” rating and a $19.00 target price for the company. Finally, Leerink Partnrs reissued a “market perform” rating on shares of Certara in a research report on Monday, February 26th. Seven research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, Certara presently has an average rating of “Hold” and an average price target of $19.64.

Read Our Latest Stock Report on CERT

About Certara

(Get Free Report)

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.

Further Reading

Insider Buying and Selling by Quarter for Certara (NASDAQ:CERT)

Receive News & Ratings for Certara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Certara and related companies with MarketBeat.com's FREE daily email newsletter.